Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2019 02:30 ET | Source: ASLAN PHARMACEUTICALS LIMITED

New Data Presented on ASLAN’s varlitinib at ESMO 2019

SINGAPORE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the presentation of...
September 30, 2019 02:35 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals and Bukwang Pharmaceutical Establish a Joint Venture, JAGUAHR Therapeutics, to Develop Novel Immuno-Oncology Therapies

- ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investing up to US$5 million - ASLAN and Bukwang will co-own new entity to develop novel...
September 19, 2019 03:50 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO

- Biliary tract cancer (BTC) patients treated with varlitinib plus capecitabine in second line achieved a response rate of 11% including two complete responses, median PFS of 2.7 months and OS of 5.8...
September 10, 2019 05:14 ET | Source: ASLAN Pharmaceuticals Limited

Abstract on ASLAN Pharmaceuticals’ Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019

SINGAPORE, Sept. 10, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on...
August 27, 2019 06:00 ET | Source: ASLAN Pharmaceuticals Limited

New Data From Aslan’s Study of Varlitinib in China Accepted as Late-Breaking Oral Presentation at 2019 CSCO Annual Meeting

SINGAPORE, Aug. 27, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that a late-breaking...
August 13, 2019 04:03 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

SINGAPORE, Aug. 13, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for...
July 31, 2019 04:14 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals to Present New Data on Varlitinib at European Society for Medical Oncology Congress

SINGAPORE, July 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on...
July 26, 2019 04:20 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Names Industry Veteran and Current Board Member Andrew Howden to Additional Role of Chairman

SINGAPORE, July 26, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that Andrew Howden...
June 04, 2019 08:00 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Completes Phase 1 Study for ASLAN004 Targeting Atopic Dermatitis

- Final results from single ascending dose study confirm ASLAN004’s favourable tolerability profile, complete inhibition of downstream mediators and potential for monthly dosing SINGAPORE, June ...
May 31, 2019 03:15 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for ASLAN004 From CSL

- Amending their previous agreement, CSL grants ASLAN full global rights to develop, manufacture and commercialise ASLAN004 SINGAPORE, May 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals...